Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea

We performed a case-control study to evaluate the association between antibiotic use and Clostridium difficile–associated diarrhea (CDAD), matching for admission unit and time at risk for CDAD. A multivariable regression model showed that treatment with fluoroquinolones (odds ratio 12.7; 95% confide...

Descripción completa

Detalles Bibliográficos
Autores principales: McCusker, Margaret E., Harris, Anthony D., Perencevich, Eli, Roghmann, Mary-Claire
Formato: Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2003
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000134/
https://www.ncbi.nlm.nih.gov/pubmed/12781017
http://dx.doi.org/10.3201/eid0906.020385
_version_ 1782193508515315712
author McCusker, Margaret E.
Harris, Anthony D.
Perencevich, Eli
Roghmann, Mary-Claire
author_facet McCusker, Margaret E.
Harris, Anthony D.
Perencevich, Eli
Roghmann, Mary-Claire
author_sort McCusker, Margaret E.
collection PubMed
description We performed a case-control study to evaluate the association between antibiotic use and Clostridium difficile–associated diarrhea (CDAD), matching for admission unit and time at risk for CDAD. A multivariable regression model showed that treatment with fluoroquinolones (odds ratio 12.7; 95% confidence interval 2.6 to 61.6) was the strongest risk factor for CDAD.
format Text
id pubmed-3000134
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-30001342010-12-16 Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea McCusker, Margaret E. Harris, Anthony D. Perencevich, Eli Roghmann, Mary-Claire Emerg Infect Dis Dispatch We performed a case-control study to evaluate the association between antibiotic use and Clostridium difficile–associated diarrhea (CDAD), matching for admission unit and time at risk for CDAD. A multivariable regression model showed that treatment with fluoroquinolones (odds ratio 12.7; 95% confidence interval 2.6 to 61.6) was the strongest risk factor for CDAD. Centers for Disease Control and Prevention 2003-06 /pmc/articles/PMC3000134/ /pubmed/12781017 http://dx.doi.org/10.3201/eid0906.020385 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Dispatch
McCusker, Margaret E.
Harris, Anthony D.
Perencevich, Eli
Roghmann, Mary-Claire
Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea
title Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea
title_full Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea
title_fullStr Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea
title_full_unstemmed Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea
title_short Fluoroquinolone Use and Clostridium difficile–Associated Diarrhea
title_sort fluoroquinolone use and clostridium difficile–associated diarrhea
topic Dispatch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3000134/
https://www.ncbi.nlm.nih.gov/pubmed/12781017
http://dx.doi.org/10.3201/eid0906.020385
work_keys_str_mv AT mccuskermargarete fluoroquinoloneuseandclostridiumdifficileassociateddiarrhea
AT harrisanthonyd fluoroquinoloneuseandclostridiumdifficileassociateddiarrhea
AT perencevicheli fluoroquinoloneuseandclostridiumdifficileassociateddiarrhea
AT roghmannmaryclaire fluoroquinoloneuseandclostridiumdifficileassociateddiarrhea

Ejemplares similares